When 62-year-old Maria Lopez blinked after her LASIK surgery, she felt nothing—no sting, no dryness, just an eerie numbness that lingered for months. She’s not alone. While most corneal injuries heal swiftly, thousands suffer lasting nerve damage, leaving them vulnerable to chronic dry eye, pain, or worse—silent corneal erosion that goes undetected. Now, a breakthrough from UConn School of Medicine offers hope. Professors Royce Mohan and Paola Bargagna-Mohan have discovered that Schwann cells in the cornea—long overlooked—hold the key to nerve regeneration, thanks to a gene called DKK1.
The cornea is the most densely innervated tissue in the human body, with nerve endings 300 to 600 times more concentrated than in the skin. These nerves aren’t just for sensation—they’re guardians, triggering blinks and tears to protect the eye’s delicate surface. But when injured—whether by surgery, chemicals like nitrogen mustard, or everyday irritants—some nerves fail to regrow. For decades, researchers targeted other cell types, but Schwann cells, which wrap around nerves like insulation, were largely ignored—until now.
Using single-cell RNA sequencing, the Mohans’ lab isolated corneal Schwann cells and made a startling discovery: these cells express DKK1, a gene never before seen in Schwann cells. More importantly, when they developed a topical DKK1 inhibitor and applied it to injured mouse corneas, nerve regeneration followed. Mice with both physical and chemical injuries regained corneal sensation as axons and Schwann cells rebuilt their network. This is the first time a therapeutic target has been identified specifically for corneal Schwann cells—a leap forward in ocular repair.
But delivering the drug was just as critical. Traditional eye drops lose over 90% of their payload with each blink, washed away by tears before they can reach the stromal layer where Schwann cells reside. The team’s solution? A patent-pending micelle-based formulation that encapsulates the DKK1 inhibitor, allowing it to penetrate deeper and stay longer. In effect, the eyedrop becomes a stealth vehicle for nerve repair.
The implications stretch beyond post-surgery recovery. Soldiers exposed to chemical weapons, industrial workers splashed with solvents, and millions with chronic dry eye could all benefit. With the formulation designed for topical use, clinical translation could be swift. As Royce Mohan puts it, "No one has ever shown a therapeutic target for Schwann cells in the cornea." Now, for the first time, a path to healing the eye’s invisible wounds is coming into focus.